Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
Recruiting
N/A
Interventional Study
Parkinson Disease
Prodromal Stage
Neurodegenerative Diseases
Basal Ganglia Diseases
Central Nervous System Diseases
Synucleinopathies
Nervous System Diseases
Cerebral Disorder
Brain Diseases
Parkinsonian Disorders
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 50 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 130 (estimated)
- Sponsor
- University Hospital, Bonn · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases. In addition to progressive motor deterioration, cognitive decline is a key element of the non-motor symptom complex of these diseases. Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) indicates an early stage of α-synucleinopathies, even before re…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
iRBD:
* Age: 50-80 years
* Polysomnographically confirmed diagnosis of iRBD
* Maximum of 120 minutes of sports/outdoor activities per day
* Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase
* Basic smartphone skills
* Sufficient knowl…
Contacts